Nivolumab Plus Cabozantinib Shows Sustained Survival Advantage in Advanced RCC
February 19th 2023The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.
89Zr-DFO-girentuximab Showcases Sensitivity, Specificity for Clear Cell RCC Imaging
February 19th 202389Zr-DFO-girentuximab demonstrated sensitivity and specificity thresholds that were exceeded by 3 independent readers for PET/CT imaging of clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.
Cabozantinib After CPI-Based Combination Therapy Showcases Early Efficacy in Advanced RCC
February 18th 2023Treatment with cabozantinib elicited responses in patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who had progressed after first-line treatment with checkpoint inhibitor–based combination therapy.
Nivolumab Displays Sustained Survival Benefits in Urothelial Carcinoma
February 18th 2023At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.
Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC
February 16th 2023The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.
Talazoparib Plus Enzalutamide Improves rPFS in First-line mCRPC
February 16th 2023Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.